Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/08 → 11/30/10 |
Funding
- Elan Pharmaceuticals PLC: $228,150.00
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers
- Jicha, Gregory (PI)
- Cambi, Franca (CoI)
- Cooper, Gregory (CoI)
- Fee, Dominic (CoI)
- Markesbery, William (CoI)
- Schmitt, Frederick (CoI)
- Smith, Charles (CoI)